Holen Sie sich die Stockscreener-App
329.71
0.73%
-2.42
Schlusskurs vom Vortag:
$332.13
Offen:
$332.14
24-Stunden-Volumen:
617.25K
Relative Volume:
0.64
Marktkapitalisierung:
$12.94B
Einnahmen:
$1.40B
Nettoeinkommen (Verlust:
$177.69M
KGV:
72.89
EPS:
4.5234
Netto-Cashflow:
$174.93M
1W Leistung:
-0.53%
1M Leistung:
-1.83%
6M Leistung:
+33.15%
1J Leistung:
+18.88%
1-Tages-Spanne:
$329.04
$332.14
1-Wochen-Bereich:
$329.04
$333.54
52-Wochen-Spanne:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
329.71 | 13.03B | 1.40B | 177.69M | 174.93M | 4.5234 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-11-18 | Eingeleitet | Wells Fargo | Underweight |
| 2025-10-08 | Hochstufung | Needham | Hold → Buy |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Penumbra Inc stock (US70975L1070): Why Google Discover changes matter more now - AD HOC NEWS
Penumbra (PEN) down 1.6% since last earnings report: Can it rebound? - MSN
Penumbra names Shruthi Narayan as president, effective September 1 - MSN
Board backs Boston Scientific acquisition of Penumbra (PEN); Special Meeting May 6, 2026 - Stock Titan
Q3 2025 Penumbra Inc Earnings Call Transcript - GuruFocus
Penumbra Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
FTC Issues Second Request for Boston Scientific and Penumbra Merger - HarianBasis.co
Penumbra Inc (NYSE:PEN) Presents a Compelling Growth and Breakout Opportunity - ChartMill
PEN Stock Price, Quote & Chart | PENUMBRA INC (NYSE:PEN) - ChartMill
Penumbra, Inc. (NYSE:PEN) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Did STORM-PE’s Strong Functional Outcomes Just Shift Penumbra's (PEN) Investment Narrative? - Sahm
Understanding Momentum Shifts in (PEN) - Stock Traders Daily
Boston Scientific’s $14.9 Billion Bet: The Strategic "Homecoming" to Neurovascular Dominance - FinancialContent
Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A - The Chronicle-Journal
Here's Why Penumbra (PEN) is a Strong Growth Stock - Yahoo Finance
Penumbra (PEN) to Release Quarterly Earnings on Wednesday - MarketBeat
RBC Capital Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374 - Moomoo
Penumbra Inc stock (US70975L1070): Why its neurovascular leadership matters more now for investors - AD HOC NEWS
Penumbra Presents STORM-PE 90-day Results at SIR - dicardiology.com
Penumbra trial shows improved outcomes for pulmonary embolism By Investing.com - Investing.com Australia
Study backs Penumbra computer-assisted thrombectomy - MassDevice
Penumbra (PEN) Reports Positive Outcomes from STORM-PE Trial - GuruFocus
Aug PreEarnings: What is the long term forecast for Penumbra Inc stock2026 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Penumbra trial shows improved outcomes for pulmonary embolism - Investing.com
New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients - Finviz
Baillie Gifford & Co. Sells 32,221 Shares of Penumbra, Inc. $PEN - MarketBeat
3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN) - Yahoo Finance
Penumbra Sale To Boston Scientific Sparks Review Of Deal Value - Yahoo Finance
Penumbra, Inc. (PEN) Stock Forecasts - Yahoo Finance
Penumbra, Inc. (PEN) stock price, news, quote and history - Yahoo Finance Australia
Fidelity Stock Selector Small Cap Fund's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra Investor Alert: Kahn Swick & Foti Investigates Proposed Sale - National Today
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc.PEN - The AI Journal
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc.PEN - FinancialContent
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Penumbra (NYSE:PEN): Strongest Q4 Results from the Medical Devices & SuppliesCardiology, Neurology, Vascular Group - Yahoo Finance
Citi Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374 - Moomoo
Penumbra (NYSE:PEN) Director Sells $32,822.00 in Stock - MarketBeat
Grewal Harpreet, Penumbra director, sells $32,822 in stock - Investing.com UK
Grewal Harpreet, Penumbra director, sells $32,822 in stock By Investing.com - Investing.com South Africa
Penumbra (NYSE: PEN) director sells 100 shares under Rule 10b5-1 plan - Stock Titan
JP Morgan Maintains Penumbra (PEN) Neutral Recommendation - MSN
Penumbra, Inc. (PEN) latest stock news and headlines - Yahoo Finance UK
PEN PE Ratio & Valuation, Is PEN Overvalued - Intellectia AI
Penumbra, Inc. (PEN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):